Exhibit 99.1 Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results § FY 2023 revenue of $233.3 million, in-line with guidance § Year-over-year, Commercial Cell & Gene Therapy revenue rose 33%; BioStorage/BioServices revenue increased 45% § Global clinical trials supported reached a record 675 NASHVILLE, Tennessee, March 12, 2024, - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport”), a global leader in supply chain solutions for cell & gene therapies, today announced financial results for the fourth q ...